News | January 04, 2013

VerifyNow II System Gains European CE

Clinical data, guideline recommendations and cost effectiveness study strengthen clinical need for platelet reactivity testing

Accumetrics VerifyNow II CE mark Antiplatelet Therapy

January 4, 2013 — Accumetrics Inc. announced that its next generation VerifyNow II System has achieved CE marking for point-of-care measurement of platelet reactivity to antiplatelet agents. This marks the culmination of a series of important milestones in 2012, increasing evidence of the clinical value of platelet reactivity testing and significantly expanding the market opportunities for the VerifyNow System in both surgical and Interventional cardiology patient populations.

The next generation system, the VerifyNow II product line, received CE mark and will launch in Europe starting early this year. The advanced system includes upgraded features and state of the art user interface that promise to further increase penetration in markets in the European Union. Future worldwide geographies are planned for introduction in 2013.

In 2012, new guidelines from the Society of Thoracic Surgery (STS) recommended platelet reactivity testing for surgical patients in order to better manage patients’ response to antiplatelet medications. These guidelines include a new Class II recommendation for patients who require urgent surgery to help determine the risk of bleeding and the timing of surgery. In the area of interventional cardiology, the much-awaited results of the 8500+ patient ADAPT DES trial were also presented at the annual Transcatheter Cardiovascular Therapeutics conference, validating the association between high platelet reactivity and one-year patient outcomes

”There have been large strides in 2012 towards solidifying the clinical role of platelet reactivity testing,” said Matthew J. Price, director of the Cardiac Catheterization Laboratory at Scripps Clinic, La Jolla, Calif. “We now have large trials and registries validating the risks associated with high platelet reactivity in PCI patients and increased data and stronger guideline recommendations for use of platelet reactivity testing to aid in determining surgical timing. Physicians can now implement platelet reactivity testing in multiple clinical settings to provide valuable information to aid in making treatment decisions for the millions of patients requiring antiplatelet agents.”

Increased focus on the cost effectiveness of platelet reactivity testing also fuelled market expansion in the United States in 2012. The availability of generic clopidogrel, along with the launch of Medicare’s 30-Day Readmissions Reduction program, raised awareness of the key role of platelet reactivity testing in supporting cost effective and clinically appropriate decision making.

“As the clinical role of platelet reactivity testing continues to gain traction in the interventional cardiology marketplace, we are pleased to see additional clinical specialties, such as surgery and interventional neuroradiology, demonstrate an increased need for platelet reactivity testing as well,” said Timothy I. Still, president and CEO of Accumetrics. “Plavix losing its patent in the United States, the inclusion of platelet reactivity testing in the recent surgical guidelines, and the availability of new medical devices that require the use of antiplatelet therapies, continue to offer new growth opportunities for our company. As the leader in platelet reactivity testing, we remain focused on producing high quality diagnostic tests that provide critical information to physicians to help improve the quality of care for patients on these life-saving antiplatelet agents.

The VerifyNow System is currently used in over 800 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

Test is indicated outside the United States for evaluating the risk for recurrent events in cardiovascular patients.

For more information: www.accumetrics.com

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Overlay Init